论文部分内容阅读
目的探讨培美曲塞联合顺铂二线治疗治疗晚期卵巢癌的疗效以及不良反应。方法经病理学或细胞学确诊的晚期卵巢癌患者41例,中位年龄48岁,KPS评分≥60。培美曲塞500mg/m2第1d+顺铂25mg/m2第1-3d,每3周为1个周期。至少2周期以上可评价疗效及不良反应。结果 41例中38例可评价疗效,无CR病例(0%),PR17例(44.74%),SD15例(39.47%),PD6例(15.79%),总有效率(CR+PR)为44.74%,临床获益率(CR+PR+SD)为84.21%。38例可评价疗效者,中位无进展生存期5.3个月,中位生存期13.2个月,1年生存率34.21%(13/38)。主要不良反应为粒细胞下降、贫血和胃肠道反应。结论培美曲塞联合铂类治疗晚期卵巢癌疗效确切,不良反应发生率低,耐受性较好。
Objective To investigate the efficacy and side effects of pemetrexed plus cisplatin in the treatment of advanced ovarian cancer. Methods Forty-one patients with advanced ovarian cancer diagnosed by pathology or cytology were studied. The median age was 48 years. The KPS score was ≥60. Pemetrexed 500mg / m2 1d + cisplatin 25mg / m2 1-3d, every 3 weeks for a cycle. At least 2 cycles can be evaluated efficacy and adverse reactions. Results There were no CR cases (0%) in 38 cases, PR17 cases (44.74%), SD15 cases (39.47%), PD6 cases (15.79%) and total effective rate (CR + PR) , The clinical benefit rate (CR + PR + SD) was 84.21%. Among 38 evaluable patients, the median progression-free survival was 5.3 months, the median survival time was 13.2 months, and the 1-year survival rate was 34.21% (13/38). The main adverse reactions were neutropenia, anemia and gastrointestinal reactions. Conclusion Pemetrexed combined with platinum treatment of advanced ovarian cancer curative effect is accurate, the incidence of adverse reactions is low, well tolerated.